ACAD Stock Overview
A biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ACAD from our risk checks.
ACADIA Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.62 |
| 52 Week High | US$33.99 |
| 52 Week Low | US$14.60 |
| Beta | 0.42 |
| 1 Month Change | -14.50% |
| 3 Month Change | -37.09% |
| 1 Year Change | -37.79% |
| 3 Year Change | -35.37% |
| 5 Year Change | -43.27% |
| Change since IPO | 118.21% |
Recent News & Updates
Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24Recent updates
Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
Jun 29Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In Growth
May 07Acadia: Catalysts Stacking
Apr 28Shareholder Returns
| ACAD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.6% | -4.5% | -1.0% |
| 1Y | -37.8% | 4.6% | 25.2% |
Return vs Industry: ACAD underperformed the US Biotechs industry which returned 4.6% over the past year.
Return vs Market: ACAD underperformed the US Market which returned 25.2% over the past year.
Price Volatility
| ACAD volatility | |
|---|---|
| ACAD Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ACAD's share price has been volatile over the past 3 months.
Volatility Over Time: ACAD's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 610 | Steve Davis | www.acadia.com |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.
ACADIA Pharmaceuticals Inc. Fundamentals Summary
| ACAD fundamental statistics | |
|---|---|
| Market cap | US$2.49b |
| Earnings (TTM) | -US$1.71m |
| Revenue (TTM) | US$813.81m |
3.0x
P/S Ratio-1,413x
P/E RatioIs ACAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACAD income statement (TTM) | |
|---|---|
| Revenue | US$813.81m |
| Cost of Revenue | US$405.08m |
| Gross Profit | US$408.73m |
| Other Expenses | US$410.44m |
| Earnings | -US$1.71m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 50.22% |
| Net Profit Margin | -0.21% |
| Debt/Equity Ratio | 0% |
How did ACAD perform over the long term?
See historical performance and comparison